Informe de análisis de tamaño, participación y tendencias del mercado mundial de terapia con células T con receptores de antígenos quiméricos (CAR): descripción general de la industria y pronóstico hasta 2031

Análisis del mercado de la terapia con células T con receptores de antígenos quiméricos (CAR)

El mercado de la terapia con células T con receptores de antígenos quiméricos (CAR) ha sido testigo de avances notables, impulsados ​​por investigaciones innovadoras y aplicaciones clínicas. La terapia con células CAR-T, que modifica las células T de un paciente para apuntar y atacar a las células cancerosas, ha demostrado una eficacia significativa en el tratamiento de varias neoplasias hematológicas , como la leucemia linfoblástica aguda y el linfoma no Hodgkin. Los desarrollos recientes incluyen la introducción de nuevos productos CAR-T, procesos de fabricación mejorados y la exploración de nuevos antígenos objetivo, lo que conduce a mejores resultados para los pacientes. Por ejemplo, empresas como Max Healthcare han lanzado terapias CAR-T en colaboración con instituciones, ampliando el acceso a estos tratamientos transformadores. Además, el aumento de la inversión en ensayos clínicos en todas las regiones, particularmente en América del Norte y Asia-Pacífico, está fomentando un panorama competitivo, lo que impulsa una mayor innovación. A medida que la terapia continúa ganando terreno, los organismos reguladores se están adaptando para agilizar los procesos de aprobación, lo que facilita un acceso más rápido a tratamientos que salvan vidas. Este dinámico entorno de mercado está preparado para un crecimiento sólido, ofreciendo oportunidades prometedoras para proveedores de atención médica, pacientes y compañías farmacéuticas por igual, a medida que el enfoque se desplaza hacia la expansión de las indicaciones y la mejora de las modalidades de tratamiento en la terapia CAR-T.

Tamaño del mercado de terapia con células T con receptor de antígeno quimérico (CAR)

El tamaño del mercado global de terapia de células T con receptores de antígenos quiméricos (CAR) se valoró en USD 2.44 mil millones en 2023 y se proyecta que alcance los USD 5.97 mil millones para 2031, con una CAGR del 11.80% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis de expertos en profundidad, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Tendencias del mercado de la terapia con células T con receptores de antígenos quiméricos (CAR)

“ Cambio creciente hacia terapias con células CAR-T alogénicas”

El mercado de terapias con células T con receptores de antígenos quiméricos (CAR) ha sido testigo de avances notables, impulsados ​​por investigaciones innovadoras y aplicaciones clínicas. Una tendencia destacada en el mercado de terapias con células T con receptores de antígenos quiméricos (CAR) es el cambio hacia terapias con células T CAR-T alogénicas, que utilizan células T modificadas genéticamente de donantes sanos en lugar de las propias células del paciente. Este enfoque tiene como objetivo mejorar la accesibilidad y reducir el tiempo de fabricación y los costos asociados con las terapias autólogas. Por ejemplo, empresas como Allogene Therapeutics están desarrollando terapias CAR-T listas para usar que pueden estar fácilmente disponibles para los pacientes, minimizando el tiempo de espera para el inicio del tratamiento. La conveniencia de las terapias CAR-T alogénicas puede mejorar significativamente los resultados del paciente, especialmente en casos urgentes donde el tiempo es crítico, como la leucemia linfoblástica aguda. Además, los ensayos clínicos en curso y el apoyo regulatorio están impulsando la innovación en este segmento, lo que convierte a las terapias con células CAR-T alogénicas en un punto focal para futuros avances en el tratamiento del cáncer y expandiendo el alcance potencial del mercado en diversas poblaciones de pacientes.

Alcance del informe y segmentación del mercado de terapia con células T con receptores de antígeno quimérico (CAR)

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Definition

Chimeric antigen receptor (CAR)-T cell therapy is an innovative form of immunotherapy that involves genetically modifying a patient's T cells to express chimeric antigen receptors. These receptors are designed to recognize specific antigens present on the surface of cancer cells. Once the T cells are modified, they are expanded in the laboratory and then infused back into the patient, where they seek out and attack the cancer cells, thereby enhancing the body’s immune response against tumors. This therapy has shown significant effectiveness in treating certain hematologic cancers, such as acute lymphoblastic leukemia and non-Hodgkin lymphoma, and is being investigated for use against various solid tumors and other malignancies.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Dynamics

Drivers

• Rising Incidence of Cancer

The global rise in cancer cases has significantly increased the demand for Chimeric Antigen Receptor (CAR)-T cell therapy among healthcare providers treating cancer patients. According to the Centers for Disease Control and Prevention (CDC), in 2019, the United States reported 1,752,735 new cancer diagnoses and 599,589 cancer-related deaths. This translates to approximately 439 new cancer cases and 146 cancer deaths for every 100,000 individuals in the population. The alarming prevalence of cancer is driving healthcare providers to increasingly adopt CAR-T cell therapy due to its numerous benefits, including targeted treatment and personalized approaches, which are expected to further propel market growth. This trend underscores the therapy's potential as a vital component in the fight against cancer, ultimately enhancing patient outcomes and survival rates.

• Rising Product Approvals

The increasing number of product approvals significantly contributes to the growth of the chimeric antigen receptor (CAR)-T cell therapy market. For instance,  the approval of CARVYKTI by the Janssen Pharmaceutical Companies of Johnson & Johnson in 2022, which received U.S. FDA clearance for treating adults with relapsed or refractory multiple myeloma (RRMM) who have undergone four or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Such advancements in approvals not only enhance treatment options for patients but also reinforce the market's momentum by encouraging further investment and research in CAR-T cell therapies. Consequently, the growing trend of product approvals is expected to be a significant driver of market growth in this sector.

Opportunities

• Rising Investments from Key Organizations

The growing investments in chimeric antigen receptor (CAR-T) cell therapy are significantly driving market expansion. For instance, in 2021, Blackstone announced that funds managed by Blackstone Life Sciences committed USD 250 million to establish a new company focused on both autologous and allogeneic universal CAR-T cell therapies, collaborating with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH. This substantial financial backing is expected to accelerate research and development efforts, ultimately leading to innovative therapies and improved treatment options for patients. Such investments enhance the therapeutic landscape and represent a significant market opportunity, as they pave the way for advancements in CAR-T cell therapies that can address unmet medical needs and improve patient outcomes.

• Increasing Cases of Multiple Myeloma

The rising incidence of multiple myeloma is projected to drive significant growth in the market for chimeric antigen receptor (CAR)-T cell therapies. According to GLOBOCAN 2020, approximately 176,000 new cases of multiple myeloma and immunoproliferative diseases were expected in 2020, with projections suggesting this figure could soar to 290,000 by 2040. Furthermore, the data indicates that individuals have a 1 in 117 chance of being diagnosed with multiple myeloma by the age of 85. This increasing prevalence highlights a critical market opportunity for CAR-T cell therapies, as healthcare providers seek innovative treatment options to address the growing patient population. The anticipated rise in cases underscores the urgent need for effective therapies, driving demand for CAR-T solutions that can offer improved outcomes for patients suffering from this challenging condition.

Restraints/Challenges

• Adverse Effects of Chimeric Antigen Receptor (CAR)-T Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapies are associated with significant side effects that can hinder market growth. One of the most critical challenges is the occurrence of cytokine release syndrome (CRS), which has been identified as one of the most common and severe adverse reactions to these treatments. CRS results from the rapid activation and proliferation of CAR T-cells, leading to the release of large quantities of cytokines, which are chemical messengers that modulate immune responses. This uncontrolled release can cause symptoms ranging from mild flu-like effects to severe, life-threatening complications such as high fever, low blood pressure, and multi-organ failure. In addition, the mass destruction of antibody-producing B cells can leave patients vulnerable to infections, further complicating their treatment journey. These serious side effects pose significant challenges for healthcare providers and patients alike, potentially limiting the widespread adoption of CAR T-cell therapies and restraining overall market growth.

• Significant Expenses Related to Chimeric Antigen Receptor (CAR)-T Cell Therapy

The substantial costs associated with CAR T-cell therapy pose a significant challenge to market growth, as they can restrict access for many patients who need this advanced treatment. The price of a single CAR T-cell therapy treatment can be exceptionally high, making it unaffordable for a large segment of the population, particularly those without adequate insurance coverage. This financial barrier limits patient access and places an enormous strain on healthcare systems, which must allocate resources to cover these expensive treatments. As a result, disparities in treatment availability may emerge, with wealthier patients gaining access while others are left without options, ultimately hindering the broader adoption and equitable distribution of CAR T-cell therapies. This situation highlights the challenge of integrating these cutting-edge therapies into standard care pathways.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Scope

The market is segmented on the basis of types, target antigen, and therapeutic application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Abecma
• Breyanzi
• Kymriah
• Tecartus
• Yescarta
• Others

Target Antigen

• CD 19
• CD 20
• GD2
• CD22
• CD30
• CD33
• HER1
• HER2
• Meso
• Egfrvlll
• Others

Therapeutic Application

• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• Non-Hodgkin Leukemia
• Multiple Myeloma
• Pancreatic Cancer
• Neuroblastoma
• Breast Cancer
• Acute Myeloid Leukemia
• Hepatocellular Carcinoma
• Colorectal Cancer
• Others

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, types, target antigen, and therapeutic application as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the chimeric antigen receptor (CAR)-T cell therapy market, driven by a strong foundation in research and commercialization. The region's advanced healthcare infrastructure and investment in innovative therapies contribute significantly to this dominance. Furthermore, the surge in clinical trials focused on T-cell therapies is expected to bolster market growth in North America throughout the forecast period.

Asia-Pacific region is anticipated to experience significant growth in the chimeric antigen receptor (CAR)-T cell therapy market, primarily due to the highest number of registered clinical trials related to these therapies. Governments in the region are making substantial investments and implementing reforms to enhance healthcare infrastructure, which will further stimulate market expansion. As these initiatives progress, they are expected to create a more favorable environment for the development and adoption of CAR-T cell therapies in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Leaders Operating in the Market Are:

• Autolus Therapeutics (U.K.)
• CARsgen Therapeutics Holdings Limited (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Sorrento Therapeutics, Inc. (U.S.)
• bluebird bio, Inc. (U.S.)
• Eureka Therapeutics Inc. (U.S.)
• Avacta Group plc (U.K.)
• Cibus Inc. (France)
• Celyad Oncology SA (Belgium)
• Fortress Biotech, Inc. (U.S.)
• Gilead Sciences, Inc. (U.S.)
• Novartis AG (Switzerland)
• Alaunos Therapeutics, Inc. (U.S.)
• Poseida Therapeutics, Inc. (U.S.)

Latest Developments in Chimeric Antigen Receptor (CAR)-T Cell Therapy Market

• In December 2023, Max Healthcare successfully introduced CAR-T cell therapy in the Delhi-NCR area, marking a significant advancement in cancer treatment options. This innovative therapy, developed in partnership with ImmunoACT, is specifically designed to combat lymphomas and leukemias, offering new hope for patients battling these challenging conditions
• In December 2022, CARsgen Therapeutics Co., Ltd. partnered with the Shanghai Cancer Institute to develop new technology that significantly enhances the antitumor effectiveness of T cells. Their research team discovered that CAR T cells engineered to overexpress Runx3 exhibited sustained antitumor activity and improved tumor control compared to traditional chimeric antigen receptor T-cell therapies
• In November 2022, Caribou Biosciences, Inc. announced that its allogeneic anti-CD19 CAR-T cell therapy, CB-010, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for relapsed or refractory large B cell lymphoma (LBCL), as well as fast track designation for relapsed or refractory B cell non-Hodgkin lymphoma
• En junio de 2022, la Universidad de Ottawa presentó resultados prometedores del ensayo clínico Canadian-Led Immunotherapies in Cancer-01 (CLIC-01), que se centró en una de las primeras terapias con células CAR-T desarrolladas en Canadá para el cáncer. Esta terapia presenta un proceso de fabricación único que puede dar lugar a opciones de tratamiento más asequibles y equitativas.
• En noviembre de 2021, la junta directiva del Instituto de Medicina Regenerativa de California aprobó una subvención de 4,1 millones de dólares para apoyar el avance de la innovadora terapia de células T con receptores de antígenos quiméricos que están desarrollando los científicos de la Facultad de Medicina de la Universidad de California en San Diego, lo que contribuye a sus esfuerzos por hacer pasar este prometedor tratamiento contra el cáncer del laboratorio a la práctica clínica.

SKU-44836